Extended Data Fig. 1: Other pipelines identified 94% of DNVs in control trios.
From: Genomic analyses implicate noncoding de novo variants in congenital heart disease
Overlaps with DNVs identified in 1,470 control trios with two other pipelines9,10. Of note, a third analysis of these trios did not include de novo calls42. For consistency with other pipelines, only SNVs were included and variants in LCRs, blacklists, segmental duplications, and repeats were excluded. Together, 94% of de novo SNVs were called by at least one other pipeline.
